ALTHOUGH not described as a "quick fix", a new therapy which has undergone phase III trials successfully may relieve children and teenagers of their fear of peanut allergy.
The data was presented at the American College of Allergy, Asthma & Immunology this month.
The protein therapy gradually introduces the allergen, desensitising the patient's immune system to the invader, and may become available late in 2019.
As in many drug-desensitisation approaches, the effect does not last without continual stimulation which means patients will need to remain on the therapy to stay protected - see acaai.org.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Nov 18
